Advertisement

Topics

Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

12:29 EDT 17 May 2019 | SCRIP

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with...

      

Related Stories

 

Original Article: Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

NEXT ARTICLE

More From BioPortfolio on "Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...